KDR and cancer: When EGFR and VEGFR2 targeting nanobodies were applied in combination, noting the particular set-up used here with human cancer cells and murine endothelial cells, no interference was observed of either nanobody–PS (VM2–PS or 7D12–PS) on the association of the other nanobody–PS (7D12–PS or VM2–PS) with cells (Figure S5).